ICU MEDICAL INC/DE (ICUI): Results of Operations and Financial Condition
ICU MEDICAL INC/DE (ICUI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., August 6, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, tod
How this was made
The 30-second read
Why it matters
The company updated FY 2026 GAAP net income, GAAP diluted EPS, Adjusted EBITDA, and diluted EPS guidance, providing a new earnings framework for traders and analysts.
Market read
This is a primary-source earnings and guidance update, with specific GAAP and non-GAAP ranges that can drive repricing and positioning ahead of subsequent quarters.
What to watch
Vital Care product line revenue fell sharply year over year, and the company’s forward-looking risk list highlights supply-chain concentration and integration/divestiture execution risks that could pressure future quarters.
ICU Medical reports second-quarter GAAP revenue growth of 1%, gross-margin expansion to 43%, higher adjusted earnings, and raises fiscal-year 2026 profit guidance.
GAAP revenue increased 1% and non-GAAP organic revenue increased 6%, while GAAP gross margin expanded to 43% from 38%, adjusted diluted EPS increased to $2.37, and fiscal-year adjusted EBITDA and diluted EPS guidance were raised. GAAP net income and diluted EPS were lower than the prior-year quarter, which included a $41,823 gain on sale of business.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesGAAP | $ 551,683 (in thousands) | – | 1% |
| Organic revenue growth excluding the impact of the IV Solutions divestiture and foreign currencynon-GAAP | 6% | – | 6% |
| Cost of goods soldGAAP | 316,630 (in thousands) | – | – |
| Gross profitGAAP | $ 235,053 (in thousands) | – | – |
| Gross marginGAAP | 43% | – | – |
| Selling, general and administrative expenseGAAP | 151,922 (in thousands) | – | – |
| Research and development expenseGAAP | 22,702 (in thousands) | – | – |
| Restructuring, strategic transaction and integration expenseGAAP | 21,302 (in thousands) | – | – |
| Total operating expensesGAAP | 195,926 (in thousands) | – | – |
| Income from operationsGAAP | 39,127 (in thousands) | – | – |
| Interest expense, netGAAP | (15,747) (in thousands) | – | – |
| Other (expense) income, netGAAP | (236) (in thousands) | – | – |
| Gain on sale of businessGAAP | — | – | – |
| Income before income taxes and equity in earnings of unconsolidated affiliatesGAAP | 23,144 (in thousands) | – | – |
| Provision for income taxesGAAP | (7,070) (in thousands) | – | – |
| Net income from consolidated companiesGAAP | 16,074 (in thousands) | – | – |
| Equity in earnings of unconsolidated affiliatesGAAP | 3,013 (in thousands) | – | – |
| Net incomeGAAP | $ 19,087 (in thousands) | – | – |
| Basic net income per shareGAAP | $ 0.76 | – | – |
| Diluted net income per shareGAAP | $ 0.76 | – | – |
| Adjusted diluted earnings per sharenon-GAAP | $2.37 | – | – |
| Adjusted EBITDAnon-GAAP | $110.0 million | – | – |
| Six-month total revenuesGAAP | $ 1,081,908 (in thousands) | – | – |
| Six-month gross profitGAAP | 441,279 (in thousands) | – | – |
| Six-month income from operationsGAAP | 52,706 (in thousands) | – | – |
| Six-month net incomeGAAP | $ 49,219 (in thousands) | – | – |
| Six-month diluted net income per shareGAAP | $ 1.96 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| ConsumablesNot provided in the document. | $ 289.3 million | – | $ 16.2 million |
| Infusion SystemsThe Chief Executive Officer said second quarter results were ahead of expectations for Infusion Systems. | $ 189.0 million | – | $ 21.3 million |
| Vital CareThe IV Solutions business, previously included within Vital Care, was disposed of on May 1, 2025. Vital Care included contract manufacturing revenue of $3.8 million, compared with $5.3 million in the prior-year quarter. | $ 73.4 million | – | $(34.6) million |
Fiscal Year 2026 outlook
- NoteGAAP net income: $73 million to $83 million, updated from $26 million to $44 million.
- NoteGAAP diluted earnings per share: $2.89 to $3.29, updated from $1.03 to $1.74.
- NoteAdjusted EBITDA: $415 million to $435 million, updated from $400 million to $430 million.
- NoteDiluted earnings per share: $8.60 to $9.00, updated from $7.75 to $8.45.
What drove it
- Second-quarter GAAP revenue increased 1% year-over-year.
- Excluding the impact of the IV Solutions divestiture and foreign currency, non-GAAP organic revenue increased 6%.
- Gross margin was 43%, compared with 38% in the prior-year quarter.
- Infusion Systems revenue was $ 189.0 million, compared with $ 167.7 million in the prior-year quarter.
- Consumables revenue was $ 289.3 million, compared with $ 273.1 million in the prior-year quarter.
Concerns
- Vital Care revenue was $ 73.4 million, compared with $ 108.0 million in the prior-year quarter; the company said the IV Solutions business was disposed of on May 1, 2025.
- GAAP net income was $ 19.1 million, compared with $ 35.3 million in the prior-year quarter.
- The prior-year quarter included a gain on sale of business of 41,823 (in thousands), while the second quarter of 2026 reported no gain on sale of business.
- Restructuring, strategic transaction and integration expense was 21,302 (in thousands), compared with 16,218 (in thousands) in the prior-year quarter.
- Long-term debt was $ 1,212,449 (in thousands) at June 30, 2026.
What to watch
- Delivery against fiscal-year 2026 GAAP net income guidance of $73 million to $83 million.
- Delivery against fiscal-year 2026 adjusted EBITDA guidance of $415 million to $435 million.
- Infusion Systems performance after second-quarter results that were ahead of management's expectations.
- The revenue trajectory in Vital Care following the May 1, 2025 IV Solutions business divestiture.
- Operating cash flow and capital expenditures following six-month net cash provided by operating activities of 119,059 (in thousands) and purchases of property, plant and equipment of (29,813) (in thousands).
Balance sheet and cash flow
- Cash and cash equivalents were $ 298,299 (in thousands) at June 30, 2026, compared with $ 307,963 (in thousands) at December 31, 2025.
- Current portion of long-term debt was $ 18,750 (in thousands) at June 30, 2026, compared with $ 18,750 (in thousands) at December 31, 2025.
- Long-term debt was $ 1,212,449 (in thousands) at June 30, 2026, compared with $ 1,265,917 (in thousands) at December 31, 2025.
- Net cash provided by operating activities was 119,059 (in thousands) for the six months ended June 30, 2026, compared with 62,538 (in thousands) for the six months ended June 30, 2025.
- Purchases of property, plant and equipment were (29,813) (in thousands) for the six months ended June 30, 2026, compared with (34,317) (in thousands) for the six months ended June 30, 2025.
- Intangible asset additions were (3,555) (in thousands) for the six months ended June 30, 2026, compared with (4,541) (in thousands) for the six months ended June 30, 2025.
- Deposit received for the sale of a business was 2,000 (in thousands) for the six months ended June 30, 2026.
Analysis
ICU Medical reported second-quarter GAAP revenue of $ 551,683 (in thousands), compared with $ 548,866 (in thousands) in the prior-year quarter. The company described this as 1% GAAP revenue growth and reported 6% non-GAAP organic revenue growth excluding the effects of the IV Solutions divestiture and foreign currency. Consumables revenue was $ 289.3 million and Infusion Systems revenue was $ 189.0 million, both higher than the prior-year quarter. Vital Care revenue was $ 73.4 million versus $ 108.0 million, with the company noting that it disposed of the IV Solutions business, previously included within Vital Care, on May 1, 2025.
Profitability improved materially at the gross-profit and operating-income levels. Gross profit was $ 235,053 (in thousands), compared with $ 208,064 (in thousands), and GAAP gross margin expanded to 43% from 38%. Total operating expenses were 195,926 (in thousands), compared with 197,477 (in thousands), while income from operations increased to 39,127 (in thousands) from 10,587 (in thousands). Adjusted EBITDA increased to $110.0 million from $100.3 million, and adjusted diluted earnings per share increased to $2.37 from $2.10.
GAAP net income was $ 19,087 (in thousands), or $ 0.76 per diluted share, compared with $ 35,338 (in thousands), or $ 1.43 per diluted share. The prior-year quarter included a gain on sale of business of 41,823 (in thousands), whereas no gain on sale of business was reported in the 2026 quarter. Restructuring, strategic transaction and integration expense increased to 21,302 (in thousands) from 16,218 (in thousands), while interest expense, net declined to (15,747) (in thousands) from (20,549) (in thousands).
For the six months ended June 30, 2026, net cash provided by operating activities was 119,059 (in thousands), compared with 62,538 (in thousands) in the prior-year period. Purchases of property, plant and equipment were (29,813) (in thousands). Cash and cash equivalents were $ 298,299 (in thousands) at June 30, 2026, while long-term debt was $ 1,212,449 (in thousands).
Management raised its fiscal-year 2026 guidance for GAAP net income, GAAP diluted earnings per share, adjusted EBITDA, and diluted earnings per share. The updated ranges are $73 million to $83 million for GAAP net income, $2.89 to $3.29 for GAAP diluted earnings per share, $415 million to $435 million for adjusted EBITDA, and $8.60 to $9.00 for diluted earnings per share. The reported guide does not provide fiscal-year revenue, gross-margin, operating-expense, or tax-rate guidance.
Management, verbatim
Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.
Vivek Jain, Chief Executive Officer
Not in the filing
stated, not guessed- Previous-release outlook was not provided; therefore, comparison of actual results with prior guidance is unavailable.
- Fiscal-year 2026 revenue guidance was not provided.
- Fiscal-year 2026 gross-margin guidance was not provided.
- Fiscal-year 2026 operating-expense guidance was not provided.
- Fiscal-year 2026 tax-rate guidance was not provided.
- Second-quarter operating cash flow was not provided; cash flow was reported for the six months ended June 30, 2026.
- Free cash flow was not provided.
- Dividends and share repurchases during the reported period were not provided.
- Quarter-over-quarter comparisons were not provided for the reported metrics.
- Percentage year-over-year changes were not provided for individual product lines.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
ICU Medical’s Q2 2026 comparisons reflect the May 1, 2025 divestiture of the IV Solutions business, with organic revenue growth excluding divestiture and FX impacts.
Ticker impact
ICU Medical reported Q2 2026 results and updated FY 2026 guidance, including GAAP net income and Adjusted EBITDA ranges.
Near-term bias higher as traders reprice FY 2026 earnings and EBITDA expectations; watch for sensitivity to the GAAP net income range widening/narrowing.
The filing provides fresh, specific quarterly datapoints (revenue, gross margin, net income, adjusted EPS/EBITDA) plus updated full-year GAAP and non-GAAP guidance ranges, which are direct inputs to valuation and positioning.
Market effects
Infusion systems and critical care suppliers may see read-across demand and margin expectations if peers are also normalizing post-divestiture portfolio effects.
Limited direct regional spillover; primarily US healthcare medtech sentiment.
Moderate, as guidance updates can influence broader hospital supply chain and medtech earnings expectations.
Counterpoint
GAAP net income declined year over year, so the headline profitability improvement may be driven by non-GAAP adjustments and portfolio effects rather than durable operating leverage.
Key entities
- issuerICU Medical, Inc.
Nasdaq-listed medical products company reporting Q2 2026 results and updating FY 2026 guidance via SEC 8-K.
- executiveVivek Jain
CEO quoted stating Q2 results were ahead of expectations for Infusion Systems and generally in line for the remainder.
